Entheon Biomedical Corp. announced that Cybin IRL Limited has delivered notice to the Company to terminate the consulting services agreement (the Consulting Agreement) entered into between the Company and Cybin that was announced on July 11, 2022 pursuant to which the Company was to provide ongoing support to the Phase 1 N,N-dimethyltryptamine study. Services under the Consulting Agreement have been fully rendered and fees payable by Cybin to the Company were accelerated as a result of the early termination.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.165 CAD | -23.26% | 0.00% | +65.00% |
04-29 | Entheon Biomedical Corp. Reports Earnings Results for the First Quarter Ended February 29, 2024 | CI |
04-18 | Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
+65.00% | 1.07M | |
+23.37% | 47.02B | |
+49.67% | 41.86B | |
-0.94% | 41.76B | |
-4.32% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- ENBI Stock
- News Entheon Biomedical Corp.
- Entheon Biomedical Corp. Announces Termination of Consulting Agreement with Cybin